ISSN Print 2500–1094
ISSN Online 2542–1204
BIOMEDICAL JOURNAL OF PIROGOV UNIVERSITY (MOSCOW, RUSSIA)
OPINION
The potential of CD4+ regulatory T cells for the therapy of autoimmune diseases
About authors
1 Institute of Biology, Karelian Research Center of RAS, Petrozavodsk, Republic of Karelia
2 Perm State Pharmaceutical Academy, Perm, Russia
3 Kemerovo State Medical University, Kemerovo, Russia
Correspondence should be addressed: Alexey V. Churov
Pushkinskaya, 11, Petrozavodsk, 186910; ur.xednay@uoruhca
About paper
Funding: the study was carried out under state order for Karelian Research Centre (ID 0218-2019-0083; Modification of transcription programs of regulatory T cell differentiation in immunoinflammatory diseases and cancer). Its publication was sponsored by Prime Papers LLC.
Acknowledgements: the authors thank the Center for Precision Genome Editing and Genetic Technologies for Biomedicine (Moscow) for consultations.
Author contribution: Churov AV — article design, literature analysis, preparation of the manuscript draft and its final version; Syutkina AI — article design, the major contribution to literature analysis, preparation of the manuscript draft and its final version; Mamashov KY — article design, literature analysis, preparation of the manuscript draft and its final version; Oleinik EK — literature analysis, preparation of the manuscript draft and its final version.
Received: 2019-11-25
Accepted: 2019-12-09
Published online: 2019-12-19
|
Despite the considerable progress in the therapy of autoimmune pathologies, the existing methods are associated with the risk of serious adverse events. We think that regulatory T cells hold great promise for the therapy of disorders caused by a breakdown in immunological self-tolerance. This article aims at estimating the possible challenges facing Treg-based clinical approaches and offers solutions to the technical issues associated with the use of these cells in the therapy of autoimmune diseases.
Keywords: autoimmune disease, CRISPR-Cas9, Treg cells, regulatory T cells, FOXP3, immunotherapy, cell therapy, CAR-Treg therapy